Premium
Potentiation of aspirin induced cardioprotection by minocycline against myocardial ischemia reperfusion injury in streptozotocin diabetic rat
Author(s) -
Bhatt Lokesh Kumar,
Addepalli Veeranjaneyulu
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.572.4
Subject(s) - medicine , minocycline , streptozotocin , aspirin , diabetes mellitus , anesthesia , ischemia , reperfusion injury , pharmacology , endocrinology , chemistry , biochemistry , antibiotics
In the present study we have targeted Matrix Metalloproteinase MMP‐2 and MMP‐9 overactivation in diabetic rats by combination of minocycline and aspirin to attenuate cardiovascular complication of diabetes. Diabetes was induced in male Wistar rats by streptozotocin (55 mg/kg i.p.). Three weeks after diabetes induction, rats were treated with minocycline (50 mg/kg, p.o.), aspirin (50 mg/kg, p.o.), or minocycline (50 mg/kg, p.o.) plus aspirin (50 mg/kg, p.o.) for a period of next three weeks. At the end of sixth week, ischemia/reperfusion injury was induced by ligating left anterior descending coronary artery for 30 min followed by 2hr reperfusion. Percentage infarct volume, arrhythmias, mortality, collagen level and MMP‐2 & MMP‐9 level were significantly increased in vehicle treated diabetic group when compared with normo‐glycemic rats. Treatment with combination of minocycline and aspirin decreased percentage infarct volume, arrhythmias, mortality & collagen level when compared with vehicle‐treated diabetic controls and showed reduced level of MMP‐2 and MMP‐9. Results of the present study suggest that minocycline potentiates cardioprotective effect of aspirin in diabetic rats by enhanced MMP‐2 & MMP‐9 inhibition. The project was funded by NMIMS University, Mumbai, India.